173 related articles for article (PubMed ID: 2902918)
21. Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells.
Itoh K; Tilden AB; Kumagai K; Balch CM
J Immunol; 1985 Feb; 134(2):802-7. PubMed ID: 3917475
[TBL] [Abstract][Full Text] [Related]
22. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
Itoh K; Tilden AB; Balch CM
J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
[TBL] [Abstract][Full Text] [Related]
23. Phenotypic analysis of a resting subpopulation of human peripheral blood NK cells: the FcR gamma III (CD16) molecule and NK cell differentiation.
Warren HS; Skipsey LJ
Immunology; 1991 Jan; 72(1):150-7. PubMed ID: 1825480
[TBL] [Abstract][Full Text] [Related]
24. CD3/Ti gamma A: a functional gamma-receptor complex expressed on human peripheral lymphocytes.
Faure F; Jitsukawa S; Triebel F; Hercend T
J Immunol; 1988 Mar; 140(5):1372-9. PubMed ID: 2964471
[TBL] [Abstract][Full Text] [Related]
25. Major histocompatibility complex-unrestricted cytolytic activity of human T cells. Analysis of precursor frequency and effector phenotype.
Patel SS; Thiele DL; Lipsky PE
J Immunol; 1987 Dec; 139(11):3886-95. PubMed ID: 3500232
[TBL] [Abstract][Full Text] [Related]
26. Infiltration of interleukin-2-inducible killer cells in ascitic fluid and pleural effusions of advanced cancer patients.
Blanchard DK; Kavanagh JJ; Sinkovics JG; Cavanagh D; Hewitt SM; Djeu JY
Cancer Res; 1988 Nov; 48(22):6321-7. PubMed ID: 2972357
[TBL] [Abstract][Full Text] [Related]
27. Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors.
Damle NK; Doyle LV; Bradley EC
J Immunol; 1986 Nov; 137(9):2814-22. PubMed ID: 2944965
[TBL] [Abstract][Full Text] [Related]
28. Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects.
Hermann GG; Geertsen PF; von der Maase H; Steven K; Andersen C; Hald T; Zeuthen J
Cancer Res; 1992 Feb; 52(3):726-33. PubMed ID: 1732060
[TBL] [Abstract][Full Text] [Related]
29. Recombinant interleukin-2-activated intracavitary lymphocytes: phenotypic characteristics and effector function.
Umiel T; Monselise J; Klein T; Rakovsky E; Fenig E; Lurie H; Adler A
J Biol Response Mod; 1989 Aug; 8(4):409-21. PubMed ID: 2787838
[TBL] [Abstract][Full Text] [Related]
30. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
[TBL] [Abstract][Full Text] [Related]
31. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
32. Lysis of tumor cells by CD3+4-8-16+ T cell receptor alpha beta- clones, regulated via CD3 and CD16 activation sites, recombinant interleukin 2, and interferon beta 1.
van de Griend RJ; Tax WJ; van Krimpen BA; Vreugdenhil RJ; Ronteltap CP; Bolhuis RL
J Immunol; 1987 Mar; 138(5):1627-33. PubMed ID: 2949018
[TBL] [Abstract][Full Text] [Related]
33. In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration.
Lotze MT; Custer MC; Sharrow SO; Rubin LA; Nelson DL; Rosenberg SA
Cancer Res; 1987 Apr; 47(8):2188-95. PubMed ID: 3030546
[TBL] [Abstract][Full Text] [Related]
34. Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.
Goldstein D; Sosman JA; Hank JA; Weil-Hillman G; Moore KH; Borchert A; Bechhofer R; Storer B; Kohler PC; Levitt D
Cancer Res; 1989 Dec; 49(23):6832-9. PubMed ID: 2819723
[TBL] [Abstract][Full Text] [Related]
35. Bacterial activation of human natural killer cells. Characteristics of the activation process and identification of the effector cell.
Tarkkanen J; Saksela E; Lanier LL
J Immunol; 1986 Oct; 137(8):2428-33. PubMed ID: 3093576
[TBL] [Abstract][Full Text] [Related]
36. The expression and functional involvement of laminin-like molecules in non-MHC restricted cytotoxicity by human Leu-19+/CD3- natural killer lymphocytes.
Schwarz RE; Hiserodt JC
J Immunol; 1988 Nov; 141(10):3318-23. PubMed ID: 3263421
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-2- and mitogen-activated NK-like killer cells from highly purified human peripheral blood T cell (CD3+ N901-) cultures.
Atzpodien J; Wisniewski D; Gulati S; Welte K; Knowles R; Clarkson B
Nat Immun Cell Growth Regul; 1987; 6(3):129-40. PubMed ID: 3114621
[TBL] [Abstract][Full Text] [Related]
38. Depressed lymphokine-activated killer activity and analysis of the precursor cells in peripheral blood of patients with hepatocellular carcinoma.
Shirai M; Watanabe S; Nishioka M
Hepatogastroenterology; 1990 Oct; 37(5):465-8. PubMed ID: 2174825
[TBL] [Abstract][Full Text] [Related]
39. Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens.
Lanier LL; Le AM; Phillips JH; Warner NL; Babcock GF
J Immunol; 1983 Oct; 131(4):1789-96. PubMed ID: 6225799
[TBL] [Abstract][Full Text] [Related]
40. Perforin expression can define CD8 positive lymphocyte subsets in pigs allowing phenotypic and functional analysis of natural killer, cytotoxic T, natural killer T and MHC un-restricted cytotoxic T-cells.
Denyer MS; Wileman TE; Stirling CM; Zuber B; Takamatsu HH
Vet Immunol Immunopathol; 2006 Apr; 110(3-4):279-92. PubMed ID: 16325923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
